Insider Transactions in Q2 2023 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+8.2%
|
$0
$0.62 P/Share
|
|
Jun 23
2023
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
11,000
-9.64%
|
$561,000
$51.07 P/Share
|
|
Jun 22
2023
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
11,000
-16.03%
|
$572,000
$52.18 P/Share
|
|
Jun 21
2023
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
11,349
-14.19%
|
$590,148
$52.26 P/Share
|
|
Jun 20
2023
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,777
-52.1%
|
$1,142,735
$55.0 P/Share
|
|
Jun 20
2023
|
William Richard White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+30.5%
|
$122,500
$7.01 P/Share
|
|
Jun 16
2023
|
Tomas J. Heyman |
SELL
Open market or private sale
|
Direct |
26,000
-100.0%
|
$1,404,000
$54.67 P/Share
|
|
Jun 16
2023
|
Tomas J. Heyman |
BUY
Exercise of conversion of derivative security
|
Direct |
26,000
+50.0%
|
$650,000
$25.04 P/Share
|
|
Jun 16
2023
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
78,200
-12.56%
|
$4,301,000
$55.32 P/Share
|
|
Jun 16
2023
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+14.85%
|
$0
$0.61 P/Share
|
|
Jun 16
2023
|
Jane Henderson |
SELL
Open market or private sale
|
Direct |
40,000
-71.88%
|
$2,160,000
$54.13 P/Share
|
|
Jun 16
2023
|
Jane Henderson |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+50.0%
|
$280,000
$7.01 P/Share
|
|
Jun 13
2023
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
606
-2.64%
|
$33,330
$55.16 P/Share
|
|
Jun 13
2023
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
538
-0.29%
|
$29,590
$55.16 P/Share
|
|
Jun 13
2023
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
509
-0.27%
|
$27,995
$55.16 P/Share
|
|
Jun 13
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
1,613
-0.39%
|
$88,715
$55.16 P/Share
|
|
Jun 13
2023
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
591
-0.73%
|
$32,505
$55.16 P/Share
|
|
Jun 01
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-1.94%
|
$1,125,000
$45.11 P/Share
|
|
Jun 01
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+2.78%
|
$75,000
$3.49 P/Share
|
|
May 19
2023
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
120,000
+18.75%
|
$5,040,000
$42.0 P/Share
|
|
May 01
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.9%
|
$1,125,000
$45.25 P/Share
|
|
May 01
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.44%
|
$0
$0.62 P/Share
|
|
Apr 18
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+8.9%
|
$0
$0.62 P/Share
|
|
Apr 03
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-3.18%
|
$950,000
$38.36 P/Share
|
|
Apr 03
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.96%
|
$0
$0.62 P/Share
|